Liraglutide Effect in Atrial Fibrillation

Korábbi kezelés

• Prior ablation for atrial fibrillation
• Patients with a serious medical condition (for example, recent cancer with chemotherapy or radiation therapy within 4 weeks before entering the study) who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
• Known contraindications to Liraglutide, such as the previous history of pancreatitis or medullary thyroid carcinoma

Más betegség

• Patients not appropriate candidates for catheter ablation such as those with AF due to acute or chronic precipitating medical conditions, for example, hypothyroidism and hyperthyroidism, significant pulmonary disease, pulmonary embolism, left atrial thrombus, class IV heart failure)
• Personal or family history of multiple endocrine neoplasias
• Known serious hypersensitivity reaction to Liraglutide
• Type 1 diabetes, defined by American Diabetes Association criteria, history of diabetic ketoacidosis, pancreas or beta-cell transplantation, or diabetes due to pancreatitis or pancreatectomy

Laborértékek

• Patients using, glitazones, sodium-glucose transporters 2 inhibitors (SGLT2i), other GLP-1 analogs, or DPP4 inhibitors
• Poorly controlled type 2 diabetes with HbA1c > 10%

Egyéb

• Inability to sign an informed consent
• Patients with longstanding persistent atrial fibrillation of more than 3 years
• Patients with a life expectancy <1 year
• Pregnant women
• Women who are breast-feeding or intend to become pregnant

• Male and female, age 18 or older
• Persistent AF defined as continuous AF sustained beyond 7 days (or AF with the decision to cardiovert before 7 days of enrollment or Paroxysmal AF defined as recurrent AF (≥2 episodes) that terminates spontaneously within 7 days
• BMI ≥27 kg/m2
• Patient wishes to undergo a catheter ablation procedure for the treatment of atrial fibrillation
• Receiving follow-up care at the University of Miami